Merus Labs International Inc. Form 6-K July 05, 2016

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 6-K

#### REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2016

Commission File No. <u>000-30082</u>

## MERUS LABS INTERNATIONAL INC.

(Translation of registrant's name into English)

100 Wellington St. West, Suite 2110 P.O. Box 151
<u>Toronto, ON M5K 1H1</u>

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-Form 20-F [ ] Form 40-F [X]	F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule $101(b)(1)$ [ ]	
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule $101(b)(7)$ [ ]	

## **SUBMITTED HEREWITH**

## **Exhibits**

99.1 Press Release dated July 4th, 2016 - Merus Announces Reduced Leverage and Provides Business Update

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: July 4, 2016

#### MERUS LABS INTERNATIONAL INC.

/s/ Andrew Patient

Andrew Patient

Chief Financial Officer